What Is Semaglutide?

1. How It Works

GLP-1 is a hormone the gut releases after a meal. It tells the pancreas to release insulin when glucose is high and to hold back glucagon, slows the stomach, and signals fullness to the brain. Native GLP-1 is cleared within minutes.

Semaglutide is the same peptide with three edits, per the label’s description section. A substitution at position 8 protects it from the enzyme that destroys native GLP-1. A fatty di-acid chain at position 26 lets it bind albumin, the blood’s carrier protein, at more than 99%, so it circulates for days instead of minutes. The result is a once-weekly injection, or a once-daily tablet once an absorption enhancer is added. The effect that follows is the same set native GLP-1 produces, held continuously: glucose-dependent insulin release, glucagon suppression, slower gastric emptying, and reduced appetite. The what is a GLP-1 page covers the receptor biology.

2. What the Trials Showed

Semaglutide has the largest trial record in the class. The numbers below are the ones that decided its labels.

The outcome trials are where semaglutide stands apart from the rest of the class. Six placebo-controlled trials have reported hard endpoints, and each one is on a label.

Weight and HbA1c are surrogates. These are the outcomes, and they are why Ozempic carries cardiovascular and kidney indications, Wegovy carries cardiovascular and MASH indications, and Rybelsus, since October 2025, carries a cardiovascular indication.

3. Pharmacokinetics

The half-life is a property of the molecule, so it is the same by every route. What changes is how much gets in. Subcutaneous injection delivers 89%. A tablet delivers a fraction of a percent, because semaglutide is a peptide and the gut digests peptides; the tablets pair it with SNAC, an absorption enhancer that lets a small share cross the stomach lining before it is destroyed. That is why tablet doses are ten times or more the injection doses, and why the label says the routes are not substitutable milligram for milligram. The bioavailability page works the arithmetic.

Missed-dose windows follow from the half-life. Ozempic allows a late dose within 5 days; Wegovy allows it while the next dose is still more than 2 days away; the tablets say skip and resume tomorrow. The missed-dose tool has each rule.

4. Safety Limits

Every semaglutide label opens with the same boxed warning: thyroid C-cell tumors in rodents, human relevance unknown, and a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

The warnings and precautions sections then cover acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or a sulfonylurea, acute kidney injury from dehydration after vomiting or diarrhea, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications in people with type 2 diabetes, and pulmonary aspiration under anesthesia. Wegovy’s label adds heart rate increase.

The common side effects are gastrointestinal and dose-related. In the Ozempic label’s pooled placebo-controlled trials, nausea occurred in 15.8% on 0.5 mg and 20.3% on 1 mg against 6.1% on placebo, vomiting in 5% and 9.2% against 2.3%, diarrhea in 8.5% and 8.8% against 1.9%. Most of it happens during dose escalation, which is why every ladder starts at a dose the label calls ineffective for glucose control and climbs in four-week or 30-day steps.

Two limits people miss. The drug is not for use in pregnancy, and the labels ask for it to be stopped at least two months before a planned pregnancy because of the long washout. And it delays gastric emptying, so the labels flag oral medicines with a narrow therapeutic window.

5. One Molecule, Five Products

Each label carries only the indications its own trials support. The comparisons that people search for are on their own pages: Ozempic vs Wegovy, Ozempic vs Rybelsus, and, against the other molecule, semaglutide vs tirzepatide.

6. Tracking Semaglutide

Because the half-life is a week, every dose overlaps the last several. A log that records product, date, milligrams, and injection site shows where the curve is and where a late dose left a gap. The half-life visualizer draws that curve, and how GLP-1 tracking works covers what to record.

7. What Is Semaglutide FAQ

• What is semaglutide in simple terms?

  A modified copy of GLP-1, a gut hormone released after eating. Native GLP-1 lasts minutes; semaglutide is altered to bind albumin and resist breakdown, so one injection lasts a week. It lowers blood sugar in a glucose-dependent way, slows the stomach, and reduces appetite.

• Is semaglutide the same as Ozempic?

  Semaglutide is the molecule. Ozempic is one of three U.S. brands that contain it, alongside Wegovy and Rybelsus. Same molecule, different labels, doses, and in Rybelsus's case a different route.

• How long does semaglutide stay in the body?

  The labels give an elimination half-life of about one week and say semaglutide is present in circulation for about five weeks after the last dose. That is why a missed weekly dose has a five-day window on Ozempic and why steady state takes four to five weeks to reach.

• Does semaglutide reduce heart attacks and strokes?

  In trials, yes. SUSTAIN-6 (type 2 diabetes) found major events in 6.6% vs 8.9% on placebo; SELECT (obesity without diabetes) 6.5% vs 8.0%; SOUL (oral semaglutide, type 2 diabetes) 12.0% vs 13.8%. Ozempic, Wegovy, and Rybelsus each carry a cardiovascular indication from one of those trials.

• What are the main risks?

  Every semaglutide label opens with a boxed warning on thyroid C-cell tumors seen in rodents and a contraindication for personal or family history of medullary thyroid carcinoma or MEN 2. Warnings cover pancreatitis, gallbladder disease, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycemia with insulin or sulfonylureas, and diabetic retinopathy complications. Nausea is the most common side effect.

8. Sources